On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...

The blood-brain barrier border protects the brain by regulating the flow of molecules, peptides, and cells, but it also keeps out many therapeutics. Now, researchers have harnessed the power of a ...

Identifying genes that control protein levels could provide insight into disease development and progression. However, genetic analyses such as genome-wide associated studies identify regions ...

Alzheimer’s is a multifaceted disease, particularly in its sporadic, late-onset form. Myriad factors—genetics, environment, cardiovascular health, metabolism, and inflammation—contribute to a ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

Part 1 of 2. Click here for Part 2. As Alzheimer’s clinicians across the U.S. started offering a disease-modifying treatment to their patients, uptake at first was slow but is now speeding up. Six ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

How does gene expression in the brain change with age? The answer remains murky, because the field has lacked a systematic, brain-wide survey of alterations across the lifespan. Researchers led by ...

How the brain’s intricate vasculature deteriorates during Alzheimer’s disease has only recently come into focus, thanks to advances in isolating and studying cerebrovascular cells. In a single-nucleus ...

A Colombian brother and sister staved off autosomal-dominant Alzheimer’s disease for 20 years past the age of onset expected based on their inheritance of the E280A Paisa presenilin mutation, ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Here’s a tau twist that may take some adapting to. CD4+ and CD8+ T cells, yes, those mercurial executioners of the immune system, may be responsible for the neurodegeneration seen in Alzheimer’s ...